Download PDF
Z Gastroenterol 2005; 43(10): 1149-1157
DOI: 10.1055/s-2005-858576
Übersicht

© Karl Demeter Verlag im Georg Thieme Verlag KG Stuttgart · New York

Lebermetastasen: Inzidenz und histogenetische Einordnung

Liver Metastases: Incidence and HistogenesisH.-U Kasper1 , U. Drebber1 , V. Dries1 , H. P. Dienes1
  • 1Institut für Pathologie der Universität zu Köln
Further Information

Publication History

Manuskript eingetroffen: 31.3.2005

Manuskript akzeptiert: 26.6.2005

Publication Date:
12 October 2005 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Metastasen sind die häufigsten bösartigen Tumoren der Leber. Im Leberregister des Institutes für Pathologie der Universität zu Köln sind seit 1996 von insgesamt 12 161 Leberproben in 1357 Fällen (11,2 %) Tumoren oder tumorähnliche Neubildungen nachgewiesen worden. Die größte Gruppe innerhalb der Neubildungen machen mit 611 Fällen (5 %) Lebermetastasen solider Tumoren aus. An 2. Stelle finden sich hepatozelluläre Karzinome (380 Fälle). Die anderen Tumoren sind seltener und schließen cholangioläre Karzinome (0,5 %), Gefäßtumoren (0,4 %), Lymphome (0,63 %), fokale noduläre Hyperplasien (0,36 %) und Leberzelladenome (0,23 %) ein. Adenokarzinome waren die häufigsten sekundären Lebertumoren mit insgesamt 400 Fällen (65,5 %), wobei 48,2 % Metastasen von Kolonkarzinomen, 13,5 % von Pankreaskarzinomen, 13 % von Mammakarzinomen, 6,2 % von Magenkarzinomen, 4,5 % von Bronchialkarzinomen und 3,7 % von Ösophaguskarzinomen waren. Mit 16 % stellen neuroendokrine Karzinome die zweithäufigste Gruppe von Lebermetastasen dar. Andere Tumorgruppen waren wesentlich seltener. Sekundäre Lebertumoren siedeln sich sehr selten in einer Leber mit Zirrhose ab. Der makroskopische Aspekt, die Histologie und die Differenzialdiagnose unter Berücksichtigung der Immunhistochemie und die Bedeutung der Leberbiopsie werden diskutiert.

Abstract

Metastases are the most common malignant tumors of the liver. In the files of the Institute of Pathology of the University of Cologne 12,161 liver tissue cases are registered. Of them, 1,357 cases (11.2 %) showed tumors or tumor like masses. Liver metastases of solid tumors were the largest group of the neoplasias with 611 cases (5.0 %) followed by hepatocellular carcinoma (380 cases; 3.1 %). Other entities were rare and include cholangiolar carcinoma (0.5 %), vascular tumors (0.4 %), lymphomas (0.4 %), focal nodular hyperplasias (0.36 %) and liver cell adenomas (0.23 %). Adenocarcinomaa are the largest group of metastases with 400 cases (65.5 %). 48.2 % of this group were metastases of colorectal cancer, 13.5 % of pancreatic cancer, 13 % of breast cancer, 6.2 % of gastric cancer, 4.5 % of lung cancer and 3.7 % of esophageal cancer. Neuroendocrine carcinomas are the second largest group with 16 % of liver filiae. Other entities were rarely found. Metastases in cirrhotic livers are seldom. The gross findings, the histology, the differential diagnosis including immunohistochemistry and the value of the liver biopsy is discussed.

Schlüsselwörter

Lebermetastasen - Prävalenz - Histologie - Pathologie - Primärtumor

Key words

Liver metastases - prevalence - histology - pathology - primary tumor

Literatur

  • 1 Dimick J B, Cowan J A Jr, Knol J A. et al . Hepatic resection in the United States: indications, outcomes, and hospital procedural volumes from a nationally representative database.  Arch Surg. 2003;  138 (2) 185-191
    PubMedGoogle Scholar
  • 2 Tot T, Samii S. The clinical relevance of cytokeratin phenotyping in needle biopsy of liver metastasis.  Apmis. 2003;  111 (12) 1075-1082
    CrossrefPubMedGoogle Scholar
  • 3 Gall E A. Primary and metastatic carcinoma of the liver. Relationship to hepatic cirrhosis.  Arch Pathol. 1960;  70 226-232
    PubMedGoogle Scholar
  • 4 Pickren J W, Tsukada Y, Lane W W. Liver metastasis: Analysis of autopsy data. Weiss L, Gilbert HA Liver metastases Boston; G.K. Hall & Co. 1982: 2-18
    Google Scholar
  • 5 Shafqat A, Merchant M, Malik I A. Clinico-pathological features and survival of patients presenting with hepatic metastases: a retrospective analysis.  J Pak Med Assoc. 1996;  46 (5) 99-102
    PubMedGoogle Scholar
  • 6 Fenster L F, Klatskin G. Manifestations of metastatic tumors of the liver. A study of eighty-one patients subjected to needle biopsy.  Am J Med. 1961;  31 238-248
    CrossrefPubMedGoogle Scholar
  • 7 Ishak K G, Goodman Z D, Stocker J T. Metastases. Tumors of the liver and Intrahepatic Bile Ducts AFIP Atlas of Tumor Pathology 1999 31: 343-349
    Google Scholar
  • 8 Schulz W, Hagen C, Hort W. The distribution of liver metastases from colonic cancer. A quantitative postmortem study.  Virchows Arch A Pathol Anat Histopathol. 1985;  406 (3) 279-284
    CrossrefPubMedGoogle Scholar
  • 9 Wigmore S J, Madhavan K, Redhead D N. et al . Distribution of colorectal liver metastases in patients referred for hepatic resection.  Cancer. 2000;  89 (2) 285-287
    CrossrefPubMedGoogle Scholar
  • 10 Shirai Y, Wakai T, Ohtani T. et al . Colorectal carcinoma metastases to the liver. Does primary tumor location affect its lobar distribution?.  Cancer. 1996;  77 (11) 2213-2216
    CrossrefPubMedGoogle Scholar
  • 11 Melato M, Laurino L, Mucli E. et al . Relationship between cirrhosis, liver cancer, and hepatic metastases. An autopsy study.  Cancer. 1989;  64 (2) 455-459
    PubMedGoogle Scholar
  • 12 Limmer A, Knolle P A. Liver sinusoidal endothelial cells: a new type of organ-resident antigen-presenting cell.  Arch Immunol Ther Exp (Warsz). 2001;  49 (Suppl 1) S7-11
    PubMedGoogle Scholar
  • 13 Varma V, Cohen C. Immunohistochemical and molecular markers in the diagnosis of hepatocellular carcinoma.  Adv Anat Pathol. 2004;  11 (5) 239-249
    PubMedGoogle Scholar
  • 14 Rocken C, Carl-McGrath S, Grantzdorffer I. et al . Ectopeptidases are differentially expressed in hepatocellular carcinomas.  Int J Oncol. 2004;  24 (3) 487-495
    PubMedGoogle Scholar
  • 15 Lamps L W, Folpe A L. The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review.  Adv Anat Pathol. 2003;  10 (1) 39-43
    CrossrefPubMedGoogle Scholar
  • 16 Fan Z, van de Rijn M, Montgomery K. et al . Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections.  Mod Pathol. 2003;  16 (2) 137-144
    CrossrefPubMedGoogle Scholar
  • 17 Van Eyken P, Sciot R, Brock P. et al . Abundant expression of cytokeratin 7 in fibrolamellar carcinoma of the liver.  Histopathology. 1990;  17 (2) 101-107
    CrossrefPubMedGoogle Scholar
  • 18 Olnes M J, Erlich R. A review and update on cholangiocarcinoma.  Oncology. 2004;  66 (3) 167-179
    CrossrefPubMedGoogle Scholar
  • 19 Riopel M A, Klimstra D S, Godellas C V. et al . Intrabiliary growth of metastatic colonic adenocarcinoma: a pattern of intrahepatic spread easily confused with primary neoplasia of the biliary tract.  Am J Surg Pathol. 1997;  21 (9) 1030-1036
    CrossrefPubMedGoogle Scholar
  • 20 Ochiai T, Yamamoto J, Kosuge T. et al . Adenosquamous carcinoma with different morphologic and histologic components arising from the intrahepatic bile duct: report of a case.  Hepatogastroenterology. 1996;  43 (9) 663-666
    PubMedGoogle Scholar
  • 21 Nakajima T, Kondo Y. A clinicopathologic study of intrahepatic cholangiocarcinoma containing a component of squamous cell carcinoma.  Cancer. 1990;  65 (6) 1401-1404
    PubMedGoogle Scholar
  • 22 Jeng Y M, Chen C L, Hsu H C. Lymphoepithelioma-like cholangiocarcinoma: an Epstein-Barr virus-associated tumor.  Am J Surg Pathol. 2001;  25 (4) 516-520
    CrossrefPubMedGoogle Scholar
  • 23 Szekely E. Lymphoepithelioma-like cholangiocarcinoma (LELC) not associated with Epstein-Barr virus.  Am J Surg Pathol. 2001;  25 (11) 1464-1466
    PubMedGoogle Scholar
  • 24 Steffani K, Erbersdobler A, Broering D C. [Primary squamous cell carcinoma of the liver. Surprising findings in dysontogenetic liver cysts].  Dtsch Med Wochenschr. 2003;  128 (38) 1947-1950
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Kaji R, Sasaki N, Tateishi I. et al . A case report of primary hepatic squamous cell carcinoma that remarkably responded to low dose arterial injection of anti-cancer drugs.  Kurume Med J. 2003;  50 (1 - 2) 71-75
    PubMedGoogle Scholar
  • 26 Moll R, Lowe A, Laufer J. et al . Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies.  Am J Pathol. 1992;  140 (2) 427-447
    PubMedGoogle Scholar
  • 27 Chu P, Wu E, Weiss L M. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases.  Mod Pathol. 2000;  13 (9) 962-972
    CrossrefPubMedGoogle Scholar
  • 28 Theodoropoulos G E, Lazaris A C, Panoussopoulos D. et al . Significance of estrogen receptors and cathepsin D tissue detection in gastric adenocarcinoma.  J Surg Oncol. 1995;  58 (3) 176-183
    PubMedGoogle Scholar
  • 29 Stenhouse G, Fyfe N, King G. et al . Thyroid transcription factor 1 in pulmonary adenocarcinoma.  J Clin Pathol. 2004;  57 (4) 383-387
    CrossrefPubMedGoogle Scholar
  • 30 Rosai J. Immunohistochemical markers of thyroid tumors: significance and diagnostic applications.  Tumori. 2003;  89 (5) 517-519
    PubMedGoogle Scholar
  • 31 Tot T. Identifying colorectal metastases in liver biopsies: the novel CDX2 antibody is less specific than the cytokeratin 20 +/7- phenotype.  Med Sci Monit. 2004;  10 (5) BR139-143
    PubMedGoogle Scholar
  • 32 Kennedy M T, Jordan R C, Berean K W. et al . Expression pattern of CK7, CK20, CDX-2, and villin in intestinal-type sinonasal adenocarcinoma.  J Clin Pathol. 2004;  57 (9) 932-937
    CrossrefPubMedGoogle Scholar
  • 33 Mesquita P, Almeida R, Van Seuningen I. et al . Coordinated expression of MUC2 and CDX-2 in mucinous carcinomas of the lung can be explained by the role of CDX-2 as transcriptional regulator of MUC2.  Am J Surg Pathol. 2004;  28 (9) 1254-1255
    PubMedGoogle Scholar
  • 34 Tornillo L, Moch H, Diener P A. et al . CDX-2 immunostaining in primary and secondary ovarian carcinomas.  J Clin Pathol. 2004;  57 (6) 641-643
    CrossrefPubMedGoogle Scholar
  • 35 Nappi O, Mills S E, Swanson P E. et al . Clear cell tumors of unknown nature and origin: a systematic approach to diagnosis.  Semin Diagn Pathol. 1997;  14 (3) 164-174
    PubMedGoogle Scholar
  • 36 Carlson J A, Slominski A, Linette G P. et al . Malignant melanoma 2003: predisposition, diagnosis, prognosis, and staging.  Am J Clin Pathol. 2003;  120 (Suppl) S101-127
    CrossrefPubMedGoogle Scholar
  • 37 Terracciano L M, Glatz K, Mhawech P. et al . Hepatoid adenocarcinoma with liver metastasis mimicking hepatocellular carcinoma: an immunohistochemical and molecular study of eight cases.  Am J Surg Pathol. 2003;  27 (10) 1302-1312
    CrossrefPubMedGoogle Scholar
  • 38 Emile J F, Theou N, Tabone S. et al . Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors.  Clin Gastroenterol Hepatol. 2004;  2 (7) 597-605
    PubMedGoogle Scholar
  • 39 Noguchi T, Takeno S, Kato T. et al . Small cell carcinoma of the esophagus; clinicopathological and immunohistochemical analysis of six cases.  Dis Esophagus. 2003;  16 (3) 252-258
    CrossrefPubMedGoogle Scholar
  • 40 Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites.  Histopathology. 2000;  36 (5) 415-420
    CrossrefPubMedGoogle Scholar
  • 41 Scott M P, Helm K F. Cytokeratin 20: a marker for diagnosing Merkel cell carcinoma.  Am J Dermatopathol. 1999;  21 (1) 16-20
    CrossrefPubMedGoogle Scholar
  • 42 Kurokawa M, Nabeshima K, Akiyama Y. et al . CD56: a useful marker for diagnosing Merkel cell carcinoma.  J Dermatol Sci. 2003;  31 (3) 219-224
    CrossrefPubMedGoogle Scholar
  • 43 Wick M R. Immunohistology of neuroendocrine and neuroectodermal tumors.  Semin Diagn Pathol. 2000;  17 (3) 194-203
    PubMedGoogle Scholar
  • 44 Lucas D R, Bentley G, Dan M E. et al . Ewing sarcoma vs lymphoblastic lymphoma. A comparative immunohistochemical study.  Am J Clin Pathol. 2001;  115 (1) 11-17
    CrossrefPubMedGoogle Scholar
  • 45 Jaffe E S. Malignant lymphomas: pathology of hepatic involvement.  Semin Liver Dis. 1987;  7 (3) 257-268
    PubMedGoogle Scholar

Dr. H.-U. Kasper

Institut für Pathologie, Universität zu Köln

Joseph-Stelzmann-Straße 9

50931 Köln

Phone: ++ 49/2 21/4 78 72 23

Fax: ++ 49/2 21/4 78 63 60

Email: hans-udo.kasper@uni-koeln.de

      >